GRIN Therapeutics Inc
GRIN Therapeutics Inc is a biotechnology company focused on developing targeted therapies for disorders driven by pathogenic variants in GRIN genes that affect NMDA receptor function. The company applies precision-medicine approaches to discover and develop small-molecule and/or biologic interventions aimed at correcting or mitigating the functional consequences of GRIN-related neurodevelopmental disorders.
Leadership & Board
- Current Number of Employees
- 6
- Current LinkedIn Followers
- 3,596
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $140M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $140M
- Latest Funding Round
- Series D
- Post-Money Valuation
- ―
Company Momentum Positive
GRIN Therapeutics Inc LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
GRIN Therapeutics Inc had 6 employees as of October 12, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
GRIN Therapeutics Inc had 3,596 followers as of October 12, 2026. The number of followers increased by 14 (0.39%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jun 27, 2025 | Series D | $140.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Blackstone Life Sciences | Series D |
| Angelini Pharma | Series D |
Similar Companies
A snapshot of private companies similar to GRIN Therapeutics Inc, helping you discover and navigate related company profiles.
